These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 10626558

  • 1. Five years of growth hormone treatment in children with Prader-Willi syndrome. Swedish National Growth Hormone Advisory Group.
    Lindgren AC, Ritzén EM.
    Acta Paediatr Suppl; 1999 Dec; 88(433):109-11. PubMed ID: 10626558
    [Abstract] [Full Text] [Related]

  • 2. Effects of growth hormone treatment on growth and body composition in Prader-Willi syndrome: a preliminary report. The Swedish National Growth Hormone Advisory Group.
    Lindgren AC, Hagenäs L, Müller J, Blichfeldt S, Rosenborg M, Brismar T, Ritzén EM.
    Acta Paediatr Suppl; 1997 Nov; 423():60-2. PubMed ID: 9401542
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of long-term continuous growth hormone treatment in children with Prader-Willi syndrome.
    de Lind van Wijngaarden RF, Siemensma EP, Festen DA, Otten BJ, van Mil EG, Rotteveel J, Odink RJ, Bindels-de Heus GC, van Leeuwen M, Haring DA, Bocca G, Houdijk EC, Hoorweg-Nijman JJ, Vreuls RC, Jira PE, van Trotsenburg AS, Bakker B, Schroor EJ, Pilon JW, Wit JM, Drop SL, Hokken-Koelega AC.
    J Clin Endocrinol Metab; 2009 Nov; 94(11):4205-15. PubMed ID: 19837938
    [Abstract] [Full Text] [Related]

  • 4. Randomized controlled GH trial: effects on anthropometry, body composition and body proportions in a large group of children with Prader-Willi syndrome.
    Festen DA, de Lind van Wijngaarden R, van Eekelen M, Otten BJ, Wit JM, Duivenvoorden HJ, Hokken-Koelega AC.
    Clin Endocrinol (Oxf); 2008 Sep; 69(3):443-51. PubMed ID: 18363884
    [Abstract] [Full Text] [Related]

  • 5. Growth Hormone Treatment in Children With Prader-Willi Syndrome: Three Years of Longitudinal Data in Prepubertal Children and Adult Height Data From the KIGS Database.
    Bakker NE, Lindberg A, Heissler J, Wollmann HA, Camacho-Hübner C, Hokken-Koelega AC, KIGS Steering Committee.
    J Clin Endocrinol Metab; 2017 May 01; 102(5):1702-1711. PubMed ID: 28323917
    [Abstract] [Full Text] [Related]

  • 6. Growth hormone treatment of children with Prader-Willi syndrome: effects on glucose and insulin homeostasis. Swedish National Growth Hormone Advisory Group.
    Lindgren AC, Hagenäs L, Ritzén EM.
    Horm Res; 1999 May 01; 51(4):157-61. PubMed ID: 10474015
    [Abstract] [Full Text] [Related]

  • 7. One-year results of growth hormone treatment of short stature in Prader-Willi syndrome.
    Hauffa BP.
    Acta Paediatr Suppl; 1997 Nov 01; 423():63-5. PubMed ID: 9440907
    [Abstract] [Full Text] [Related]

  • 8. Physical effects of growth hormone treatment in children with Prader-Willi syndrome.
    Myers SE, Carrel AL, Whitman BY, Allen DB.
    Acta Paediatr Suppl; 1999 Dec 01; 88(433):112-4. PubMed ID: 10626559
    [Abstract] [Full Text] [Related]

  • 9. Eight years of growth hormone treatment in children with Prader-Willi syndrome: maintaining the positive effects.
    Bakker NE, Kuppens RJ, Siemensma EP, Tummers-de Lind van Wijngaarden RF, Festen DA, Bindels-de Heus GC, Bocca G, Haring DA, Hoorweg-Nijman JJ, Houdijk EC, Jira PE, Lunshof L, Odink RJ, Oostdijk W, Rotteveel J, Schroor EJ, Van Alfen AA, Van Leeuwen M, Van Pinxteren-Nagler E, Van Wieringen H, Vreuls RC, Zwaveling-Soonawala N, de Ridder MA, Hokken-Koelega AC.
    J Clin Endocrinol Metab; 2013 Oct 01; 98(10):4013-22. PubMed ID: 24001750
    [Abstract] [Full Text] [Related]

  • 10. Response to growth hormone treatment in Prader-Willi syndrome: auxological criteria versus genetic diagnosis.
    Scheermeyer E, Hughes I, Harris M, Ambler G, Crock P, Verge CF, Craig ME, Bergman P, Werther G, van Driel M, Davies PS, Choong CS.
    J Paediatr Child Health; 2013 Dec 01; 49(12):1045-51. PubMed ID: 23781979
    [Abstract] [Full Text] [Related]

  • 11. Effects of growth hormone therapy on glucose metabolism and insulin sensitivity indices in prepubertal children with Prader-Willi syndrome.
    Crinò A, Di Giorgio G, Manco M, Grugni G, Maggioni A.
    Horm Res; 2007 Dec 01; 68(2):83-90. PubMed ID: 17337902
    [Abstract] [Full Text] [Related]

  • 12. The behavioral impact of growth hormone treatment for children and adolescents with Prader-Willi syndrome: a 2-year, controlled study.
    Whitman BY, Myers S, Carrel A, Allen D.
    Pediatrics; 2002 Feb 01; 109(2):E35. PubMed ID: 11826245
    [Abstract] [Full Text] [Related]

  • 13. Final height data, body composition and glucose metabolism in growth hormone-treated short children born small for gestational age.
    Hokken-Koelega AC, van Pareren Y, Sas T, Arends N.
    Horm Res; 2003 Feb 01; 60 Suppl 3():113-4. PubMed ID: 14671407
    [Abstract] [Full Text] [Related]

  • 14. Low dose growth hormone treatment in infants and toddlers with Prader-Willi syndrome is comparable to higher dosage regimens.
    Scheermeyer E, Harris M, Hughes I, Crock PA, Ambler G, Verge CF, Bergman P, Werther G, Craig ME, Choong CS, Davies PSW, PWS and OZGROW collaboration.
    Growth Horm IGF Res; 2017 Jun 01; 34():1-7. PubMed ID: 28427039
    [Abstract] [Full Text] [Related]

  • 15. Growth hormone treatment and adverse events in Prader-Willi syndrome: data from KIGS (the Pfizer International Growth Database).
    Craig ME, Cowell CT, Larsson P, Zipf WB, Reiter EO, Albertsson Wikland K, Ranke MB, Price DA, KIGS International Board.
    Clin Endocrinol (Oxf); 2006 Aug 01; 65(2):178-85. PubMed ID: 16886957
    [Abstract] [Full Text] [Related]

  • 16. Growth hormone treatment of children with Prader-Willi syndrome affects linear growth and body composition favourably.
    Lindgren AC, Hagenäs L, Müller J, Blichfeldt S, Rosenborg M, Brismar T, Ritzén EM.
    Acta Paediatr; 1998 Jan 01; 87(1):28-31. PubMed ID: 9510443
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Bone mineral density and effects of growth hormone treatment in prepubertal children with Prader-Willi syndrome: a randomized controlled trial.
    de Lind van Wijngaarden RF, Festen DA, Otten BJ, van Mil EG, Rotteveel J, Odink RJ, van Leeuwen M, Haring DA, Bocca G, Mieke Houdijk EC, Hokken-Koelega AC.
    J Clin Endocrinol Metab; 2009 Oct 01; 94(10):3763-71. PubMed ID: 19622627
    [Abstract] [Full Text] [Related]

  • 19. Effects of growth hormone treatment on height, weight, and obesity in Taiwanese patients with Prader-Willi syndrome.
    Lin HY, Lin SP, Tsai LP, Chao MC, Chen MR, Chuang CK, Huang CY, Tsai FJ, Chou IC, Chiu PC, Huang CH, Yen JL, Lin JL, Kuo PL.
    J Chin Med Assoc; 2008 Jun 01; 71(6):305-9. PubMed ID: 18567561
    [Abstract] [Full Text] [Related]

  • 20. Safety and effectiveness of growth hormone therapy in infants with Prader-Willi syndrome younger than 2 years: a prospective study.
    Corripio R, Tubau C, Calvo L, Brun C, Capdevila N, Larramona H, Gabau E.
    J Pediatr Endocrinol Metab; 2019 Aug 27; 32(8):879-884. PubMed ID: 31271556
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.